Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04594369 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis
A Phase 3 study, sponsored by Insmed Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,767
- Enrollment target
NCT04594369 is a Phase 3 study that has completed, run by Insmed Incorporated. The registered enrollment target is 1,767 participants.
The verdict
NCT04594369, a Phase 3 study, has completed, sponsored by Insmed Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,767 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
Interventions
- DRUG Placebo
- DRUG Brensocatib 10 mg
- DRUG Brensocatib 25 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,767 participants |
| Start Date | 2020-12-01 |
| Est. Completion | 2024-10-28 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04594369
The ClinicalTrials.gov registry entry for NCT04594369 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,767 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Insmed Incorporated, which has 31 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT04594369 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04594369 about?
NCT04594369 is a clinical study titled "A Study to Assess the Efficacy, Safety, and Tolerability of Brensocatib in Participants With Non-Cystic Fibrosis Bronchiectasis". The primary objective of this study is to evaluate the effect of brensocatib at 10 mg and 25 mg compared with placebo on the rate of pulmonary exacerbations (PEs) over the 52-week treatment period.
What is the current status of trial NCT04594369?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,767 participants. The study started on 2020-12-01. Estimated completion is 2024-10-28.
What interventions are being tested in trial NCT04594369?
The interventions under investigation include: Placebo (DRUG), Brensocatib 10 mg (DRUG), Brensocatib 25 mg (DRUG).
Who is sponsoring clinical trial NCT04594369?
This trial is sponsored by Insmed Incorporated, which has 31 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.